Cargando…

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes

(1) Background: Oral semaglutide represents the first oral GLP-1 RA approved for the treatment of type 2 diabetes mellitus (T2DM). This real-world retrospective study aimed at evaluating its effectiveness and tolerability in the treatment of patients with T2DM when patients switched from a glucose-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Candido, Riccardo, Gaiotti, Sara, Giudici, Fabiola, Toffoli, Barbara, De Luca, Federica, Velardi, Valerio, Petrucco, Alessandra, Gottardi, Chiara, Manca, Elena, Buda, Iris, Fabris, Bruno, Bernardi, Stella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532177/ https://www.ncbi.nlm.nih.gov/pubmed/37762991 http://dx.doi.org/10.3390/jcm12186052

Ejemplares similares

Switchover phenomenon induced by epidemic seeding on geometric networks
por: Ódor, Gergely, et al.
Publicado: (2021)

Preliminary Study on the Effect of a Night Shift on Blood Pressure and Clock Gene Expression
por: Toffoli, Barbara, et al.
Publicado: (2023)

Children With Short Stature Display Reduced ACE2 Expression in Peripheral Blood Mononuclear Cells
por: Tonon, Federica, et al.
Publicado: (2022)

Sex Differences in Proatherogenic Cytokine Levels
por: Bernardi, Stella, et al.
Publicado: (2020)

Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
por: Bernardi, Stella, et al.
Publicado: (2017)

Tie-Bar Elongation Based Filling-To-Packing Switchover Control and Prediction of Injection Molding Quality
por: Chen, Jian-Yu, et al.
Publicado: (2019)

SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients - a Real World Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2020)

Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia
por: Tonon, Federica, et al.
Publicado: (2022)

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment
por: Jamal, Qazi Mohammad Sajid
Publicado: (2020)

TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
por: Toffoli, Barbara, et al.
Publicado: (2021)

Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System
por: Toffoli, Barbara, et al.
Publicado: (2016)

A prospective study on the efficacy of patient simulation in heart and lung auscultation
por: Bernardi, Stella, et al.
Publicado: (2019)

Meta-analysis on the Association Between Thyroid Hormone Disorders and Arterial Stiffness
por: Bernardi, Stella, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
por: Morieri, Mario Luca, et al.
Publicado: (2023)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Renal mineralocorticoid receptor expression is reduced in lipoatrophy
por: Toffoli, Barbara, et al.
Publicado: (2019)

Acute Kidney Injury Associated With Semaglutide
por: Leehey, David J., et al.
Publicado: (2021)

Oral Semaglutide: Dosage in Special Situations
por: Kalra, Sanjay, et al.
Publicado: (2022)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Initial Ablation Ratio Predicts Volume Reduction and Retreatment After 5 Years From Radiofrequency Ablation of Benign Thyroid Nodules
por: Bernardi, Stella, et al.
Publicado: (2021)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

A Review on the Efficacy and Safety of Oral Semaglutide
por: Niman, Stephanie, et al.
Publicado: (2021)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Semaglutide in renal ischemia-reperfusion injury in mice
por: Tiba, Al-Tameemi, et al.
Publicado: (2023)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Acute Pancreatitis in a Patient Taking Semaglutide
por: Patel, Femina, et al.
Publicado: (2023)

Characterization of the Distal Polyadenylation Site of the ß-Adducin (Add2) Pre-mRNA
por: Costessi, Luisa, et al.
Publicado: (2013)

Long-distance regulation of Add2 pre-mRNA3′end processing
por: Nedeljkovic, Mirjana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_apkkop47lj24maae42jco2omu1